⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 13, 2024

Figure S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations

Ursula Grazini Aleksandra Markovets Lucy Ireland Daniel O’Neill Benjamin Phillips Man Xu Matthias Pfeifer Tereza Vaclová Matthew J. Martin Ludovic Bigot Luc Friboulet Ryan J. Hartmaier Maria Emanuela Cuomo Simon T. Barry Paul D. Smith Nicolas Floc’h

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Figure S1: AURA3 with pre-existing alterations in PTEN/PIK3CA-osimertinib arm.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Grazini et al. (2024) studied this question.

synapsesocial.com/papers/68e58a5ab6db643587526461 https://doi.org/10.1158/1078-0432.27013646.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
2Figure S3 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
3Figure S4 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
4Data from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
5Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024

Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
Figure S5 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024